Are there specific patient populations where ruxolitinib is more effective than azacitidine alone?

Are there specific patient populations where ruxolitinib works better than azacitidine alone?

Ruxolitinib is used in myelofibrosis and polycythemia vera, often in patients who have failed or cannot tolerate hydroxyurea. Azacitidine is a hypomethylating agent commonly used in myelodysplastic syndromes and acute myeloid leukemia. The two agents are sometimes combined for patients with myelofibrosis or AML with associated myelofibrosis.